SPOTLIGHT: Replydine halts Phase III to conserve cash


Replidyne has stopped enrollment in its Phase III trial of faropenem, a chronic bronchitis treatment. The company said the move is designed to "conserve its cash assets and support initiatives that include pursuing strategic transactions and maintaining its research programs." Replydine's release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.